First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Journal of Clinical Oncology · 20.11.2024 · 42 (33) · 3926-3934
DOI: 10.1200/jco.24.01125 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2024. Verfasst von Georgina V Long und 19 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Melanoma, Nivolumab, Ipilimumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Nivolumab plus relatlimab and nivolumab plus ipilimumab have been approved for advanced melanoma on the basis of the phase II/III RELATIVITY-047 and phase III CheckMate 067 trials, respectively. As no head-to-head trial comparing these regimens exists, an indirect treatment comparison was conducted using patient-level data from each trial. METHODS Inverse probability of treatment weighting (IPTW) adjusted for baseline characteristic differences. Minimum follow-ups (RELATIVITY-047, 33 months; CheckMate 067, 36 months) were selected to best align assessments. Outcomes included progression-free survival (PFS), confirmed objective response rate (cORR), and melanoma-specific survival (MSS) per investigator; overall survival (OS); and treatment-related adverse events (TRAEs). A Cox regression model compared PFS, OS, and MSS. A logistic regression model compared cORRs. Subgroup analyses were exploratory. RESULTS After IPTW, key baseline characteristics were balanced for nivolumab plus relatlimab (n = 339) and nivolumab plus ipilimumab (n = 297). Nivolumab plus relatlimab demonstrated similar PFS (hazard ratio [HR], 1.08 [95% CI, 0.88 to 1.33]), cORR (odds ratio, 0.91 [95% CI, 0.73 to 1.14]), OS (HR, 0.94 [95% CI, 0.75 to 1.19]), and MSS (HR, 0.86 [95% CI, 0.67 to 1.12]) to nivolumab plus ipilimumab. Subgroup comparisons showed larger numerical differences favoring nivolumab plus ipilimumab with acral melanoma, BRAF -mutant melanoma, and lactate dehydrogenase >2 × upper limit of normal, but were limited by small samples. Nivolumab plus relatlimab was associated with fewer grade 3-4 TRAEs (23% v 61%) and any-grade TRAEs leading to discontinuation (17% v 41%). CONCLUSION Nivolumab plus relatlimab demonstrated similar efficacy to nivolumab plus ipilimumab in the overall population, including most—but not all—subgroups, and improved safety in patients with untreated advanced melanoma. Results should be interpreted with caution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD.
- Dana-Farber Cancer Institute, Boston, MA.
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
- The Royal Marsden NHS Foundation Trust, London, United Kingdom.
- University of Michigan, Ann Arbor, MI.
ORCID-Profile: Georgina V Long, Evan J Lipson, Paolo A Ascierto, James Larkin, Jean-Jacques Grob, Andriy Moshyk, Zheng-Yi Zhou, Yiqiao Xin, Leon A Sakkal, Hussein Tawbi, Dirk Schadendorf
Zitieren
APA
Long, G. V., Lipson, E. J., Hodi, F. S., Ascierto, P. A., Larkin, J., Lao, C., Grob, J. J., Ejzykowicz, F., Moshyk, A., Garcia-Horton, V., Zhou, Z. Y., Xin, Y., Palaia, J., McDonald, L., Keidel, S., Salvatore, A., Patel, D., Sakkal, L. A., Tawbi, H., & Schadendorf, D. (2024). First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of Clinical Oncology, 42(33), 3926-3934. https://doi.org/10.1200/jco.24.01125
Vancouver
Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, et al. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Journal of Clinical Oncology. 2024;42(33):3926-3934. doi:10.1200/jco.24.01125
BibTeX
@article{Long2024,
author = {Long, Georgina V and Lipson, Evan J and Hodi, F Stephen and Ascierto, Paolo A and Larkin, James and Lao, Christopher and Grob, Jean-Jacques and Ejzykowicz, Flavia and Moshyk, Andriy and Garcia-Horton, Viviana and Zhou, Zheng-Yi and Xin, Yiqiao and Palaia, Jennell and McDonald, Laura and Keidel, Sarah and Salvatore, Anthony and Patel, Divya and Sakkal, Leon A and Tawbi, Hussein and Schadendorf, Dirk},
title = {First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {33},
pages = {3926--3934},
doi = {10.1200/jco.24.01125}
}
EUVIMED